Neurocrine Biosciences Announces Board Member’s Retirement
Executive Summary
Neurological and endocrine-based diseases specialist Neurocrine Biosciences Inc. has announced that W. Thomas Mitchell will be retiring from the board of directors just prior to the 2016 annual meeting of shareholders. Mitchell has been a member of the board for over 13 years, serving in various capacities on the audit, compensation, nominating and corporate governance committees.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.